CClinicalTrials.gg
Status unknownNCT02997618Updated Oct 17, 2018

The AAA Get Fit Trial: A Pilot Randomised Controlled Trial of Community Based Exercise in Patients With Abdominal Aortic Aneurysms

An interventional study of Community based exercise programme and Control in Aortic Aneurysm, Abdominal, sponsored by University of Manchester. Status unknown. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by University of Manchester · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

Rupture of abdominal aortic aneurysms(AAA) causes 12,000 deaths/year in the UK.1 Elective repair to prevent this carries a perioperative mortality of 4.5% for open surgery and 1% for endovascular repair. This risk is associated with poor cardiorespiratory fitness which can be measured using Cardiopulmonary Exercise Testing(CPET) with the CPET variables, peak oxygen uptake(peakVO2)\<15ml/kg/min and anaerobic threshold(AT)\<10.2ml/kg/min identifying patients at increased risk of early death after AAA repair.3 These variables can therefore be used as surrogate markers for cardiovascular fitness and risk of mortality and morbidity in AAA surgery; optimising these markers should improve fitness and decrease this risk. The optimal duration and type of exercise training for improving peak VO2 and AT in AAA patients is not known. AAA patients are unique as they are motivated to reduce the risk of impending surgery but are afforded the time to improve their fitness as repair may not be needed for months or even years.

The investigators propose a pilot randomised controlled trial to explore the effectiveness of a 20-week community (either home or gym-based) exercise programme to achieve sustained improvements in peak VO2 and AT, as measured by CPET, in AAA patients. Changes in QoL, habitual activity levels and cardiovascular risk will also be assessed. The results will inform a definitive multicentre clinical trial on exercise to improve outcomes in elderly patients with cardiovascular disease and AAA.

02

Conditions studied

  • Aortic Aneurysm, Abdominal
03

In context

Aneurysm

960 studies on the registry are indexed under Aneurysm; 175 are open to participants now.

This study's planned enrollment of 58 is below the median of 72 across 462 interventional studies indexed under Aneurysm.

Browse Aneurysm studies →

Lead sponsor

University of Manchester is the lead sponsor of 194 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Men with an AAA ≥ 3.0 and \< 5.0 cm and women with a AAA ≥ 3.0 and \< 4.5 cm
  2. Aged 60 - 85 years inclusive
  3. Willing and able to engage in gym- and/or home-based exercise training and undertake CPET

Exclusion criteria

Exclusion Criteria:

  1. Unable or unwilling to undertake CPET or exercise training Patients unwilling will not be able to give informed consent and those who are unable would not be able to be randomised to the intervention study group nor undergo satisfactory testing to obtain our outcome measures.
  2. High levels of habitual physical activity (those scoring "high" on the PASE questionnaire) These patients already have a high level of physical activity and therefore it may not be possible to improve their fitness any further which is the primary objective of the study.

    Exclusion criteria 3-10 are all based on medical conditions which would mean either exercise training may be unsafe, they would require further investigation and treatment of that medical condition or are likely to need upcoming intervention for their medical condition which would take priority over any participation in a research study. If any medical conditions are discovered during the study, these patients will be withdrawn from the study and referred to the necessary health professional.

  3. Severe liver disease (INR > 2, serum albumin \< 3.0g/dL, bilirubin > 50µmol/L)
  4. Unstable angina, angina of \< 2 month's duration, occurring more than twice daily, angina that is increasing in frequency or precipitated by less exertion, angina at rest
  5. Uncontrolled atrial fibrillation (AF) or other arrhythmia: untreated paroxysmal AF
  6. Moderate or severe aortic valve stenosis (peak systolic pressure gradient >40mmHg or with an aortic valve area \< 1cm2)
  7. Class II/III/IV heart failure and/or left ventricular ejection fraction \< 25%
  8. Pericarditis or myocarditis within last six months
  9. Patients with > 2mm ST depression on exercise ECG will not be eligible to take part and will be referred to a cardiologist for further assessment.
  10. Diagnosis or treatment for a malignancy over the previous 12 months
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Active comparator
    Control

    1. Usual care (control) Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to: Smoking Exercise Weight Diet

    Other: Control

  • Experimental
    Community Based Exercise Programme

    Community based-exercise (in addition to usual care) with the choice of either: 1. Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment. 2. Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises. Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks.

    Behavioral: Community based exercise programme

Interventions

  • BehavioralCommunity based exercise programme

    20 week community (home or gym based) exercise programme

  • OtherControl

    Usual care consisting of advice.

06

What researchers measure

Primary outcomes

  1. Peak VO2 as measured by CPET

    Time frame: at 20 weeks

Secondary outcomes

  1. Anaerobic Threshold as measured by CPET

    Time frame: at 20 weeks

  2. Biomarkers of Cardiovascular disease risk

    Time frame: at 20 weeks

  3. Other risk factors of Cardiovascular disease risk

    Weight, BMI, Waist Circumference and Blood Pressure

    Time frame: at 20 weeks

  4. Subjective measure of habitual activity levels (PASE questionnaire)

    Time frame: at 20 weeks

  5. Objective measure of habitual activity levels (via Accelerometry)

    Time frame: at 20 weeks

  6. Health-related quality of life

    Time frame: at 20 weeks

  7. Early changes in outcome measures

    All outcome measures will also be measured at 10 weeks and compared with other time intervals.

    Time frame: at 10 weeks

  8. Sustainability of changes in outcome measures

    All outcome measures recorded 10 weeks post cessation of exercise at 30 weeks and compared with the other time intervals.

    Time frame: at 30 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02997618
Lead sponsor
University of Manchester
Collaborators
Manchester University NHS Foundation Trust
Responsible party
Charles McCollum (Professor, University of Manchester) — Principal investigator
First posted
Dec 20, 2016
Start date
Nov 2018 (estimated)
Primary completion
Jan 2019 (estimated)
Completion
Apr 2019 (estimated)
Last update
Oct 17, 2018

Study contacts

Adam Haque, MBChB, MRCS
Contact
adam.haque@manchester.ac.uk
01612915848
Charles McCollum, MD, FRCS
principal investigator · University of Manchester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion